Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Monster Beverage Is Already Huge. Can It Keep Growing?
Key PointsMonster Beverage is growing rapidly in overseas markets.
This Top Ethereum Rival Has More Than Doubled in Two Weeks. But Is It a Buy?
Key PointsNEAR is carving out a niche in agentic AI applications.
NGX market cap hits record N164 trillion as trading volume surges
Trading activity on the Nigerian Exchange Limited (NGX) experienced a surge in liquidity on Monday, September 28, 2026, as total equity trading volume crossed the one-billion mark, reaching…
